MediWound Ltd./$MDWD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Ticker
$MDWD
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Yavne, Israel
Employees
111
ISIN
IL0011316309
Website
MediWound Ltd. Metrics
BasicAdvanced
$209M
-
-$2.06
-
-
Price and volume
Market cap
$209M
52-week high
$22.51
52-week low
$14.14
Average daily volume
66K
Financial strength
Current ratio
2.153
Quick ratio
1.989
Long term debt to equity
20.542
Total debt to equity
20.542
Interest coverage (TTM)
-39.72%
Profitability
EBITDA (TTM)
-20.082
Gross margin (TTM)
14.39%
Net profit margin (TTM)
-110.45%
Operating margin (TTM)
-108.73%
Effective tax rate (TTM)
-0.20%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-19.87%
Return on equity (TTM)
-77.92%
Valuation
Price to revenue (TTM)
10.435
Price to book
6.69
Price to tangible book (TTM)
6.71
Price to free cash flow (TTM)
-10.498
Free cash flow yield (TTM)
-9.53%
Free cash flow per share (TTM)
-184.52%
Growth
Revenue change (TTM)
-3.21%
Earnings per share change (TTM)
48.75%
3-year revenue growth (CAGR)
-4.88%
10-year revenue growth (CAGR)
52.85%
3-year earnings per share growth (CAGR)
-17.19%
10-year earnings per share growth (CAGR)
-12.76%
MediWound Ltd. News
AllArticlesVideos
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
GlobeNewsWire·2 months ago
MediWound to Report First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MediWound Ltd. stock?
MediWound Ltd. (MDWD) has a market cap of $209M as of July 01, 2025.
What is the P/E ratio for MediWound Ltd. stock?
The price to earnings (P/E) ratio for MediWound Ltd. (MDWD) stock is 0 as of July 01, 2025.
Does MediWound Ltd. stock pay dividends?
No, MediWound Ltd. (MDWD) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next MediWound Ltd. dividend payment date?
MediWound Ltd. (MDWD) stock does not pay dividends to its shareholders.
What is the beta indicator for MediWound Ltd.?
MediWound Ltd. (MDWD) does not currently have a Beta indicator.